{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:07:19Z","timestamp":1761588439887,"version":"build-2065373602"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05994-1","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T06:22:23Z","timestamp":1759126943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biological therapy in a patient with coexistence of multiple sclerosis and ankylosing spondylitis: a case based review"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-7078","authenticated-orcid":false,"given":"Iva","family":"\u017dagar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0317-006X","authenticated-orcid":false,"given":"Marita","family":"Babi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8716-4654","authenticated-orcid":false,"given":"Kristina Kova\u010d","family":"Durmi\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1279-3928","authenticated-orcid":false,"given":"Nadica Lakta\u0161i\u0107","family":"\u017derjavi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7416-1868","authenticated-orcid":false,"given":"Porin","family":"Peri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"5994_CR1","doi-asserted-by":"publisher","unstructured":"Fominykh V, Shevtsova T, Arzumanian N, Brylev L (2017) Coexistence of multiple sclerosis and ankylosing spondylitis: Report of four cases from Russia and review of the literature. J Clin Neurosci. 44:230\u2013233. https:\/\/doi.org\/10.1016\/j.jocn.2017.06.031. Epub 2017 Jul 3. PMID: 28684154","DOI":"10.1016\/j.jocn.2017.06.031"},{"issue":"3\u20134","key":"5994_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000351248","volume":"70","author":"A Lourbopoulos","year":"2013","unstructured":"Lourbopoulos A, Ioannidis P, Boura E, Antoniadis D, Karacostas D, Grigoriadis N (2013) Coexistence of multiple sclerosis and ankylosing spondylitis: report of two cases. Eur Neurol 70(3\u20134):149\u2013154. https:\/\/doi.org\/10.1159\/000351248Epub 2013 Jul 30. PMID: 23921512","journal-title":"Eur Neurol"},{"key":"5994_CR3","doi-asserted-by":"publisher","unstructured":"van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 47(6):1531-4. https:\/\/doi.org\/10.1212\/wnl.47.6.1531. PMID: 8960740","DOI":"10.1212\/wnl.47.6.1531"},{"issue":"3","key":"5994_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","year":"1999","unstructured":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53(3):457\u2013465 PMID: 10449104","journal-title":"Neurology"},{"key":"5994_CR5","doi-asserted-by":"publisher","unstructured":"Katz Sand IB, Lublin FD (2013) Diagnosis and differential diagnosis of multiple sclerosis. Continuum (Minneap Minn). 19(4 Multiple Sclerosis):922\u2009\u2013\u200943. https:\/\/doi.org\/10.1212\/01.CON.0000433290.15468.21. PMID: 23917094","DOI":"10.1212\/01.CON.0000433290.15468.21"},{"key":"5994_CR6","doi-asserted-by":"publisher","unstructured":"Compston A, Coles A (2008) Multiple sclerosis. Lancet. 372(9648):1502-17. https:\/\/doi.org\/10.1016\/S0140-6736(08)61620-7. PMID: 18970977","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"5994_CR7","doi-asserted-by":"publisher","unstructured":"Weiner HL (2004) Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 61(10):1613-5. https:\/\/doi.org\/10.1001\/archneur.61.10.1613. PMID: 15477521","DOI":"10.1001\/archneur.61.10.1613"},{"key":"5994_CR8","doi-asserted-by":"publisher","unstructured":"Roach ES (2004) Oct;61(10):1615-6 Is multiple sclerosis an autoimmune disorder? Arch Neurol. https:\/\/doi.org\/10.1001\/archneur.61.10.1615. PMID: 15477522","DOI":"10.1001\/archneur.61.10.1615"},{"issue":"10","key":"5994_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm1651","volume":"13","author":"H Kebir","year":"2007","unstructured":"Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13(10):1173\u20131175. https:\/\/doi.org\/10.1038\/nm1651Epub 2007 Sep 9. PMID: 17828272; PMCID: PMC5114125","journal-title":"Nat Med"},{"issue":"1","key":"5994_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2353\/ajpath.2008.070690","volume":"172","author":"JS Tzartos","year":"2008","unstructured":"Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172(1):146\u2013155 Epub 2007 Dec 21. PMID: 18156204; PMCID: PMC2189615","journal-title":"Am J Pathol"},{"key":"5994_CR11","doi-asserted-by":"publisher","unstructured":"Oksenberg JR, Panzara MA, Begovich AB, Mitchell D, Erlich HA, Murray RS, Shimonkevitz R, Sherritt M, Rothbard J, Bernard CC, Steinman L Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature. 1993;362(6415):68\u201370. https:\/\/doi.org\/10.1038\/362068a0. PMID: 7680433","DOI":"10.1038\/362068a0"},{"issue":"9","key":"5994_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/1352458510375708","volume":"16","author":"G Deretzi","year":"2010","unstructured":"Deretzi G, Kountouras J, Koutlas E, Zavos C, Polyzos S, Rudolf J, Grigoriadis N, Gavalas E, Boziki M, Tsiptsios I (2010) Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Mult Scler 16(9):1091\u20131101 Epub 2010 Jul 16. PMID: 20639270","journal-title":"Mult Scler"},{"issue":"4","key":"5994_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A (2022) Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol 18(4):205\u2013216. https:\/\/doi.org\/10.1038\/s41584-022-00761-zEpub 2022 Mar 10. PMID: 35273385","journal-title":"Nat Rev Rheumatol"},{"key":"5994_CR14","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4274\/tnd.2019.87513","volume":"25","author":"B Say","year":"2019","unstructured":"Say B, Ergun U (2019) Coexistence of ankylosing spondylitis and multiple sclerosis: trigger with TNF-alpha antagonist therapy or coincidental? Turk J Neurol 25:184\u2013186","journal-title":"Turk J Neurol"},{"issue":"12","key":"5994_CR15","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00296-022-05181-5","volume":"42","author":"MA Brown","year":"2022","unstructured":"Brown MA, Kenna TJ, Wordsworth BP (2022) The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our Understanding and management of disease. Rheumatol Int 42(12):2161\u20132170. https:\/\/doi.org\/10.1007\/s00296-022-05181-5","journal-title":"Rheumatol Int"},{"issue":"6","key":"5994_CR16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3390\/brainsci15060588","volume":"15","author":"M Iwan","year":"2025","unstructured":"Iwan M, W\u00f3jtowicz W, Milczarek J, Wyroba N, Wydrych Z, Falger O et al (2025) The relationship between autoimmune disorders and multiple sclerosis: clinical insights and therapeutic approaches. Brain Sci 15(6):588. https:\/\/doi.org\/10.3390\/brainsci15060588","journal-title":"Brain Sci"},{"key":"5994_CR17","unstructured":"Hanrahan PS, Russell AS, McLean DR (1988) Ankylosing spondylitis and multiple sclerosis: an apparent association? J Rheumatol. 15(10):1512-4. PMID: 3264579"},{"key":"5994_CR18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1172\/JCI58649","volume":"122","author":"A Nylander","year":"2012","unstructured":"Nylander A, Hafler DA (2012) Multiple sclerosis. J Clin Invest 122:1180\u20131188","journal-title":"J Clin Invest"},{"key":"5994_CR19","first-page":"S26","volume":"27","author":"RD Inman","year":"2009","unstructured":"Inman RD, El-Gabalawy HS (2009) The immunology of ankylosing spondylitis and rheumatoid arthritis: a tale of similarities and dissimilarities. Clin Exp Rheumatol 27:S26\u2013S32","journal-title":"Clin Exp Rheumatol"},{"key":"5994_CR20","doi-asserted-by":"publisher","unstructured":"Konen FF, M\u00f6hn N, Witte T, Schefzyk M, Wiestler M, Lovric S et al (2023) Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmun Rev. 22(5):103312. https:\/\/doi.org\/10.1016\/j.autrev.2023.103312. PMID: 36924922","DOI":"10.1016\/j.autrev.2023.103312"},{"key":"5994_CR21","doi-asserted-by":"publisher","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 373(26):2534\u20132548. https:\/\/doi.org\/10.1056\/NEJMoa1505066. PMID: 26699169","DOI":"10.1056\/NEJMoa1505066"},{"key":"5994_CR22","doi-asserted-by":"publisher","unstructured":"Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muhlen CA et al (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum. 64(2):350\u2013359. https:\/\/doi.org\/10.1002\/art.33317. PMID: 21905001","DOI":"10.1002\/art.33317"},{"issue":"2","key":"5994_CR23","doi-asserted-by":"publisher","first-page":"385394","DOI":"10.1002\/acn3.51282","volume":"8","author":"E Fern\u00e1ndezD\u00edaz","year":"2021","unstructured":"Fern\u00e1ndezD\u00edaz E, P\u00e9rezVicente JA, VillaverdeGonz\u00e1lez R, BerenguerRuiz L, CandeliereMerlicco A, MartinezNavarro ML et al (2021) Realworld experience of Ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol 8(2):385394. https:\/\/doi.org\/10.1002\/acn3.51282","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"5994_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","volume":"8","author":"L Huangfu","year":"2023","unstructured":"Huangfu L, Li R, Huang Y, Wang S et al (2023) The IL17 family in diseases: from bench to bedside. Signal Transduct Target Ther 8(1):402. https:\/\/doi.org\/10.1038\/s41392-023-01620-3","journal-title":"Signal Transduct Target Ther"},{"key":"5994_CR25","unstructured":"https:\/\/www.cosentyxhcp.com\/rheumatology"},{"issue":"1\u20132","key":"5994_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.03.004","volume":"234","author":"A Caminero","year":"2011","unstructured":"Caminero A, Comabella M, Montalban X (2011) Tumor necrosis factor alpha (TNF-\u03b1), anti-TNF-\u03b1 and demyelination revisited: an ongoing story. J Neuroimmunol 234(1\u20132):1\u20136","journal-title":"J Neuroimmunol"},{"key":"5994_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cellimm.2018.09.001","volume":"339","author":"Z Omidian","year":"2019","unstructured":"Omidian Z, Ahmed R, Giwa A, Donner T, Hamad ARA (2019) IL-17 and limits of success. Cell Immunol 339:33\u201340. https:\/\/doi.org\/10.1016\/j.cellimm.2018.09.001PMID: 30765202; PMCID: PMC7879974","journal-title":"Cell Immunol"},{"key":"5994_CR28","doi-asserted-by":"crossref","unstructured":"Madill E, Galetta K, Opeyemi O, Pua DK, Gandelman S, Chitnis T, Bhattacharyya S (2025) Safety and efficacy of anti-IL-17A use in multiple sclerosis and comorbid rheumatological disease: a multi-center exploratory study. J Clin Neurosci. 136:111211. doi: 10.1016\/j.jocn.2025.111211. Epub 2025 Apr 1. PMID: 40174548","DOI":"10.1016\/j.jocn.2025.111211"},{"issue":"6","key":"5994_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2217\/imt-2021-0128","volume":"14","author":"MA Eksin","year":"2022","unstructured":"Eksin MA, Erden A, G\u00fcven SC, Armagan B, Ozdemir B, Karakas O et al (2022) Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review. Immunotherapy 14(6):401\u2013408. https:\/\/doi.org\/10.2217\/imt-2021-0128","journal-title":"Immunotherapy"},{"key":"5994_CR30","doi-asserted-by":"publisher","unstructured":"Chi LJ, Xu WH, Zhang ZW, Huang HT, Zhang LM, Zhou J (2010) Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 15(4):345\u2013356. https:\/\/doi.org\/10.1111\/j.1529-8027.2010.00294.x. PMID: 21199106","DOI":"10.1111\/j.1529-8027.2010.00294.x"},{"key":"5994_CR31","doi-asserted-by":"publisher","unstructured":"Tan H, Zhou L, Zhao C, Quan C, ZhangBao J (2024) Multiple sclerosis associated with adalimumab use in ankylosing spondylitis. Neurol Sci. 45(8):4055\u20134058. https:\/\/doi.org\/10.1007\/s10072-024-07514-8. PMID: 38594426","DOI":"10.1007\/s10072-024-07514-8"},{"issue":"Suppl 6","key":"5994_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00415-008-6020-z","volume":"255","author":"A Winkelmann","year":"2008","unstructured":"Winkelmann A, Patejdl R, Wagner S, Benecke R, Zettl UK (2008) Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol 255(Suppl 6):109\u2013114","journal-title":"J Neurol"},{"issue":"9","key":"5994_CR33","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00415-010-5591-7","volume":"257","author":"AG Tristano","year":"2010","unstructured":"Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 257(9):1421\u20131431","journal-title":"J Neurol"},{"issue":"8","key":"5994_CR34","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1007\/s00415-021-10460-6","volume":"268","author":"R Cortese","year":"2021","unstructured":"Cortese R, Prosperini L, Stasolla A, Haggiag S, Villani V, Simone IL et al (2021) Clinical course of central nervous system demyelinating neurological adverse events associated with AntiTNF therapy. J Neurol 268(8):2895\u20132899. https:\/\/doi.org\/10.1007\/s00415-021-10460-6","journal-title":"J Neurol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05994-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05994-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05994-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:02:40Z","timestamp":1761588160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05994-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["5994"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05994-1","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient for publication of this case-based review and any accompanying images or clinical information, in accordance with ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"242"}}